EGFR and neoplasm: More specifically, Fan et al reported that the EGFR inhibitor gefitinib or the pan-PI3K inhibitor LY294002 given as monotherapy had no impact on tumor burden in a GBM model, yet when these inhibitors were used in combination, they blocked tumor growth [78].